Dr. John S. Albin, MD, PHD
Infectious Disease (Infectious Disease Physician)
- Medicare participating
At a glance
- Medical school
- University of Minnesota Medical School (2014)
- Years since graduation
- 12
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 104
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Medical school: University of Minnesota Medical School
- 2014Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Infectious Disease Physician primary
MA license 269392 -
Internal Medicine Physician
MA license 269392
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Massachusetts General Hospital Boston, MA
- Newton-Wellesley Hospital Newton, MA
- North Shore Medical Center - Salem, MA
Medical groups
- Massachusetts General Physicians Organization Inc (3,558 clinicians)
- Mass General Brigham Medical Group Northern Massachusetts Inc (827 clinicians)
- Mass General Brigham Medical Group Suburban Massachusetts Inc (602 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 104
- Services billed
- 230
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 55 | 32 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 42 | 12 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 36 | 20 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 30 | 29 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 15 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Azithromycin Other prescribers in Boston, MA | 41 |
| Atovaquone-Proguanil Hcl (atovaquone/proguanil hcl) | 25 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $4,500 in total to this clinician.
| Mannkind Corporation | $4,500 |
|---|
| Compensation for services other than consulting (speaking, faculty) | $4,500 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Mannkind Corporation Aug 21, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,500 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $42,498 in research payments for these studies, mostly to the institutions running them.
- ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension
Mannkind Corporation · Terminated · NCT06418711
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.